Utah Medical Products Stock Price and Value Analysis

Utah Medical Products (NasdaqGS:UTMD) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Utah Medical Products to reach your target.

Target type

UTMD Free Cash Flow Trend

Free Cash Flow trendline for UTMD
Free Cash Flow trendline for Utah Medical Products
CSV

Based on historical returns, we believe that Utah Medical Products can grow its free cash at a rate of about 20%. That's positive!

AdvantagesDisadvantages
  • This stock is available at a great discount!
  • This company is making money at a great rate!
  • This company has stable growth.
  • This company has an average dividend yield.
  • This company is less known than others.

Inside the UTMD Numbers

UTMD Price
(Utah Medical Products stock price per share)
$69.49
[?] UTMD Fair Price
(based on intrinsic value)
$282.58
[?] UTMD Safety Price (based on a variable margin of safety) $169.55
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 2% higher than other Healthcare stocks
[?] PE Ratio versus Industry 37% higher than other Medical Devices stocks
[?] Cash Yield 6.97%
[?] Free Cash Flow Jitter 18%
[?] Dividend Yield 1.75% (tax impact)
Shares Shorted 151,293

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 151,293 shares shorted. With 2,452,828 shares available for purchase and an average trading volume over the past 10 trading days of 21,530, it would take at least 7.0 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2009 706698 6.8
2010 706698 6.2
2011 706698 10.6
2012 706698 12.9
2013 706698 11.7
2014 706698 14.7
2015 706698 13.4
2016 706698 13.5
2017 706698 15.6
2018 706698 15.5
2019 706698 15.9
2020 706698 18.8
2021 706698 20.4
2022 706698 20.5
2023 706698 21.6
2024 706698 14.2
2025 706698 14.2

Download the yearly data as CSV.

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $170 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In the 10 of those years with dividend payment facts, dividends paid totaled $46.3 million, 27.2% of the estimated free cash flow of those years. Estimated free cash flow was at least the dividends paid in 10 of those 10 years.

In 5 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $39 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, dividends and cash spent repurchasing shares together were $12.3 million, 87.1% of estimated free cash flow of $14.2 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 13.5 3.9 n/a 3.9 29.0%
2017 15.6 3 n/a 3 18.9%
2018 15.5 4 1.2 5.2 33.7%
2019 15.9 4.1 0.4 4.5 28.4%
2020 18.8 4.1 7 11.1 59.0%
2021 20.4 11.5 n/a 11.5 56.2%
2022 20.5 3.2 2.5 5.7 27.6%
2023 21.6 4.3 n/a 4.3 19.8%
2024 14.2 4.3 20 24.2 170.5%
2025 14.2 4 8.4 12.3 87.1%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $25.9 million in 2009 and $38.5 million in 2025, a compound annual growth rate of 2.5% over 16 years.

Revenue fell 5.8% from 2024 to 2025.

Our estimated free cash flow was $14.2 million in 2025, 36.8% of revenue. In 2009 the estimated margin was 26.1%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2009 25.9 6.8 26.1%
2010 25.1 6.2 24.5%
2011 37.9 10.6 28.0%
2012 41.6 12.9 31.1%
2013 40.5 11.7 29.0%
2014 41.3 14.7 35.6%
2015 40.2 13.4 33.3%
2016 39.3 13.5 34.3%
2017 41.4 15.6 37.7%
2018 42 15.5 37.0%
2019 46.9 15.9 33.8%
2020 42.2 18.8 44.6%
2021 49.1 20.4 41.6%
2022 52.3 20.5 39.2%
2023 50.2 21.6 43.0%
2024 40.9 14.2 34.7%
2025 38.5 14.2 36.8%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $85.8 million against total liabilities of $3.3 million, or 2619.3% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 2.7% of total assets in 2025, compared with 8.4% in 2010, a decrease of 5.7 percentage points.

Stockholders equity was $119 million in 2025, compared with $37.8 million in 2010, a rise of 215.6%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 41.5% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2010 41.2 3.8 3.4 37.8
2011 76.4 6.5 35.6 40.8
2012 76.9 8.9 26 51
2013 80.7 14.4 20.1 60.6
2014 81.1 19.3 16.5 64.6
2015 79.2 23.3 9.5 69.6
2016 76.2 26.3 6.9 69.2
2017 92.7 39.9 14.6 78.1
2018 99.8 51.1 10.8 89
2019 110 42.8 8.7 101
2020 112 51.6 8.9 103
2021 116 61 8.5 107
2022 124 75.1 9.6 114
2023 135 92.9 7.1 128
2024 123 83 5.1 117
2025 123 85.8 3.3 119

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $69.49, our model's value equals that price if free cash flow grows an average of -9.6 percent a year over the 10 projection years. Our model assumes 20.2 percent a year for this stock, so the price implies growth of -9.6 percent, which is below the 20.2 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

A negative rate means the price matches our model's value only if free cash flow shrinks by that average each year over the 10 years.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $13.8 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $55.59 -20.6%
Current price $69.49 -9.6%
20 percent above the current price $83.39 -3.8%
Our model (stored fair price) $282.58 20.2%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

With the price at $69.49, Utah Medical Products is below both our safe value ($169.55) and our fair value ($282.58).

Every one of the 17 fiscal years we have for Utah Medical Products under its current filer shows positive free cash flow.

Comparing the first and last three years of data, average free cash flow rose sharply: $7.8 million at the start and $16.7 million most recently.

Year-to-year variability in free cash flow is fairly steady, measured at 18%.

These figures are automated calculations from SEC filings and the recent price. They are not a recommendation to buy or sell. See how we estimate value.

The dividend yield for Utah Medical Products is 1.75%.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 2% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 37% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to Utah Medical Products, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Utah Medical Products (UTMD) 198 20.8 1.7% 7.0% 75% below
Electromed (ELMD) 188 16.7 - - 248% above
InfuSystem Holdings (INFU) 287 32.6 - - 402% above
Tactile Systems Technology (TCMD) 573 24.9 - - 162% above
IRadimed Corporation (IRMD) 1,036 43.3 1.0% - 995% above
CONMED Corporation (CNMD) 1,382 19.2 - 5.6% 35% below
LeMaitre Vascular (LMAT) 1,684 27.1 1.3% - 328% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 706698.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-21
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: UTMD annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in UTMD

Does Utah Medical Products have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: UTMD

This example shows how we apply the Trendshare checklist to UTMD: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 69.49
    • Market cap: $198M
    • EPS: 3.34
  2. Step 2 — Valuation checks

    • P/E: 20.805
    • FCF yield: 7.0%
    • Date checked: Nov 21, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.